

Bayesian sequential analysis of adverse events with binary data

Jiayue Wang* and Ben Boukai†

Department of Mathematical Sciences, Indiana University Indianapolis
Indianapolis, Indiana, 46202

April 7, 2025

Abstract

We propose a Bayesian Sequential procedure to test hypotheses concerning the Relative Risk between two specific treatments based on the binary data obtained from the two-arm clinical trial. Our development is based on the optimal sequential test of Wang and Boukai (2024), which is cast within the Bayesian framework. This approach enables us to provide, in a straightforward manner based on the Stopping Rule Principle (SRP), an assessment of the various error probabilities via posterior probabilities and conditional error probabilities. Additionally, we present the connection to the notion of the Uniformly Most Powerful Bayesian Test (UMPBT). To illustrate our procedure, we utilized the data from Silva, Kulldorff, and Katherine Yih (2020) to analyze the results obtained from the standard Bayesian and the modified Bayesian test of Berger, Boukai, and Wang (1997) under several different prior distributions of the parameters involved.

Keywords: Bayesian Sequential test; Relative Risk; conditional error probabilities; Decision role.

AMS Classification: 62L10, 62L12, 62C10

1 Introduction

Consider a clinical experiment involving a finite population of N_0 patients. The patients arrive sequentially and are classified according to two binary attributes; whether they were assigned to receive one of the two available treatments A or B and whether they exhibited a particular side effect (*Yes* or *No*) of interest. Having classified in this manner the first n patients, ($1 \leq n \leq N_0$), the results are summarized in the following 2×2 table, Table 1 below.

For a give n , the distribution of these four counts is the multinomial distribution, so that,

$$\underline{n} = (n_{00}, n_{10}, n_{01}, n_{11})' \sim \mathcal{MN}(n, \underline{p}),$$

*Email: jwa9@iu.edu

†Email: bboukai@iu.edu

Table 1: Table of n items with two treatment groups

		<i>Presenting Side Effect</i>		
		<i>No</i> : $Y = 0$	<i>Yes</i> : $Y = 1$	
<i>Treatment Group</i>	<i>A</i>	n_{00}	n_{01}	n_A
	<i>B</i>	n_{10}	n_{11}	$n_B := n - n_A$
Totals:		$n - S_n^Y$	S_n^Y	n

where $\underline{p} := (p_{00}, p_{10}, p_{01}, p_{11})'$ is the vector of the corresponding probabilities, $\sum_i \sum_j p_{ij} = 1$ along with $\sum_i \sum_j n_{ij} = n$. Note that the counts in Table 1 follow, marginally for a given n , the Binomial distribution, $n_{ij} \sim \mathcal{B}(n, p_{ij})$, $i, j = 0, 1$. In fact, as our sampling of units for classification is conducted sequentially, one-at-a-time, we find it useful to denote by $\underline{z}^{(k)} = (z_{00,k}, z_{10,k}, z_{01,k}, z_{11,k})' \sim \mathcal{MN}(1, \underline{p})$, with $\sum_i \sum_j z_{ij,k} = 1$, for each sampling stage $k = 1, 2, \dots$ in which case,

$$\underline{n} = \sum_{k=1}^n \underline{z}^{(k)}, \quad \text{and} \quad n_{ij} = \sum_{k=1}^n z_{ij,k},$$

In the design of the two-arm clinical trial, in which the patients (who are arriving sequentially) are assigned, **at random**, to receive one of two available treatments, with some known probability p_0 , and $q_0 := 1 - p_0$, respectively, will result with $n_A = n_{00} + n_{01}$ of the patients receiving treatment *A* and $n_B := n - n_A$ of them receiving treatment *B*. Accordingly, for a given n ,

$$n_A \sim \mathcal{B}(n, p_0), \quad \text{with} \quad p_0 \equiv p_{00} + p_{01}, \quad (p_0 \text{ fixed and known}),$$

Similarly, given n , $n_B \sim \mathcal{B}(n, q_0)$. Once assigned to one of the two treatment groups, the patients are subsequently observed, during a fixed-length monitoring window, for an 'event' of interest, such as the post-treatment expression of an adverse side effect, which we generically denote $Y = 1$ for 'present' and $Y = 0$ for a 'absent'. We denote by ϑ_A and by ϑ_B the conditional probability for expressing (presenting) the monitored side effect given the patient received treatment *A* or treatment *B*, respectively. Accordingly, we have

$$\vartheta_A = \Pr(Y = 1 \mid \text{Group } A) \quad \text{and} \quad \vartheta_B = \Pr(Y = 1 \mid \text{Group } B),$$

as well as

$$p_{00} = (1 - \vartheta_A) \times p_0, \quad \text{and} \quad p_{01} = \vartheta_A \times p_0,$$

so that $p_{00} + p_{01} = p_0$ as desired by design.

For such a study, one is interested in making inference concerning the unknown probabilities ϑ_A and ϑ_B , and more importantly, concerning the **Relative Risk** (RR) of the two treatments to express the monitored side effect, namely, $\gamma = \vartheta_A/\vartheta_B$. Note that under this two-arm clinical trial, the (total) probability for presenting the monitored side effect, which we denote by η , is therefore

$$\Pr(Y = 1) = \vartheta_A p_0 + \vartheta_B q_0 = \eta.$$

Hence, we immediately obtain that given an observed side effect, the conditional probability it may be attributed to Treatment *A* as,

$$\theta(\gamma) := \Pr(\text{Group } A \mid Y = 1) = \frac{\vartheta_A p_0}{\eta} = \frac{\vartheta_A p_0}{\vartheta_A p_0 + \vartheta_B q_0} \equiv \frac{1}{1 + z_0/\gamma}, \quad (1)$$

where we have put $z_0 = (1 - p_0)/p_0$ to indicate the **known** matching odds of patients assigned to the treatment B rather than to treatment A . The matching ratio z_0 could be thought as the ratio of the number of patients assigned to treatment B relative to the number of patients assigned to treatment A .

Having classified the first n patients according to the above table, we denote by $S_n^Y := n_{01} + n_{11}$ the total number of patients presenting the monitored side effect (i.e.: $Y = 1$) and we denote by $X \equiv n_{01}$ the number of patients **in treatment group** A that presented the monitored side effect. Clearly, given n , $X \sim \mathcal{B}(n, p_{01} = \vartheta_A \times p_0)$. However, since also given n , $S_n^Y \sim \mathcal{B}(n, \eta)$ we have that given n and $\{S_n^Y = m\}$, $X \sim \mathcal{B}(m, \theta(\gamma))$. Silva, Kulldorff, and Katherine Yih (2020), R. Silva, Maro, and Kulldorff (2021) and Silva and Zhuang (2022) refer to m as the 'time' index for this two-arm binomial experiment. Accordingly, given n , the statistic S_n^Y can be used for inference on the unknown parameter η , whereas, given n and $\{S_n^Y = m\}$, the count, X , (out of m) can be used for inference on the unknown parameter $\theta(\gamma)$ and hence of the Relative Risk parameter γ .

For the 'simple' $\mathcal{B}(n, \eta)$ case, Wang and Boukai (2024) considered the sequential test

$$H_0 : \eta \leq \eta_0 \quad \text{against} \quad H_1 : \eta > \eta_0, \quad (2)$$

for some specified η_0 , $\eta_0 \in (0, 1)$, which continues the sampling process as long as the null hypothesis, H_0 , is not rejected, and stops the sampling process once there is sufficient 'evidence' to reject it. More specially, for given desired probabilities of the Type I error, α and the Type II error, β at a given $\eta_1 > \eta_0$, they determined the corresponding sample size N_0^* and a critical (boundary) test value k^* needed to achieve an 'optimal' fixed-sample UMP test of the hypotheses in (2). Since the observations leading to the data in Table 1 become available, sequentially, one-at-a-time or in batches, the collection of the data ceases once the observed total number of patients exhibiting the monitored side effect, S_n^Y , exceeds the predefined threshold k^* , leading to the *stopping time*,

$$M = \inf\{n > k^* : S_n^Y > k^*\}, \quad (3)$$

which has the Negative Binomial distribution, $M \sim \mathcal{NB}(k^*+1, \eta)$ on the integers $\{k^*+1, k^*+2, \dots\}$. Accordingly, the proposed (α, β) -optimal sequential test of (2) may be written as:

$$\text{Test}_{\text{seq}} := \begin{cases} \text{if } M \leq N_0^* & \text{stop and reject } H_0 \text{ in (2)} \\ \text{if } M > N_0^* & \text{do not reject } H_0 \text{ in (2)} \end{cases}. \quad (4)$$

Note that, in either case, the final number of observations, at 'termination', is $M^* = \min\{M, N_0^*\}$, which is the total number of observations collected and used to arrive at a conclusion of the test for (2). Note, however, that unlike the Sequential Probability Ratio Test (SPRT), the sequential collection of the data under the stopping rule (3) is continued as long as H_0 is not rejected. Accordingly, upon 'termination' (either by reaching the maximal number of observations N_0^* or by rejecting H_0 beforehand), $S_{M^*}^Y \in \{0, 1, 2, \dots, k^* + 1\}$.

Kulldorff et al. (2011), Silva, Kulldorff, and Katherine Yih (2020) have considered the above two-arm binomial experiment and the Relative Risk (RR), $\gamma = \vartheta_A/\vartheta_B$, of the two treatments to present the monitored side effect. Thus they considered the testing problem of the hypotheses concerning the parameter γ , in the form

$$H_0 : \gamma = 1 \quad \text{against} \quad H_1 : \gamma > 1, \quad (5)$$

which are equivalent to the hypotheses $H_0 : \vartheta_A = \vartheta_B$ against $H_1 : \vartheta_A > \vartheta_B$. They proposed an elaborate alpha-spending approach for calculating the 'stopping-rule' for the sequential test of the

hypotheses in (5), concerning the Relative Risk, γ . R. Silva, Maro, and Kulldorff (2021) presented a linear programming framework to determine optimal alpha spending that minimizes expected time to signal, or expected sample size as needed, leading to bound the width of the confidence interval for γ at the terminal analysts.

For a specified matching allocation ratio between the control group and the treatment group, z_0 , we denote $\theta_0 := (1 + z_0)^{-1}$. We note that the hypotheses in (5) can be stated equivalently in terms of $\theta \equiv \theta(\gamma) \equiv \gamma/(z_0 + \gamma)$ as

$$H_0 : \theta = \theta_0 \quad (\text{i.e. with } \gamma = 1) \quad \text{against} \quad H_1 : \theta > \theta_0 \quad (\text{i.e. with } \gamma > 1). \quad (6)$$

For instance, if the matching allocation ratio is 1 : 1 (balanced), then $z_0 = 1$ and therefore $\theta_0 = 1/2$, leading to the test of

$$H_0 : \theta = 1/2 \quad \text{against} \quad H_1 : \theta > 1/2.$$

Hence, the optimal sequential test of Wang and Boukai (2024) for hypotheses in the form of (2) can be applied in this current situation too.

In Section 2, we consider the testing problem of general hypotheses in the form of (6) and related inference problems to the Relative Risk, γ , entirely within the Bayesian framework. Instead of determining a value of θ under H_1 to calculate the sequential test statistics, the Bayesian sequential test uses the entire alternative support to calculate the corresponding Bayes Factor. The resulting sequential Bayesian test does not necessitate any alpha-spending calculations (of the type provided by Silva, Kulldorff, and Katherine Yih (2020)). Additionally, we present a modified Bayesian test (as was advocated in Berger, Boukai, and Wang (1997)) which benefits from the easily calculated conditional error probabilities and has both the classical (conditional) frequentist as well as Bayesian interpretation.

In Section 3, we apply our Bayesian sequential test and the modified Bayesian sequential test to the data discussed in Silva, Kulldorff, and Katherine Yih (2020) and Silva and Zhuang (2022) under different alternatives as well as different priors. Specifically, based on the modified Bayesian test, we calculate the conditional Type I or Type II error probability for each data point with corresponding decision we make. Furthermore, we connect our results to the Uniformly Most Powerful Test (UMPBT) which can be compared from the frequentist perspective. In Section 4, we compare our results with the results presented in Silva, Kulldorff, and Katherine Yih (2020) and Silva and Zhuang (2022) and provide some closing remarks.

2 The Bayesian framework for Binomial Probabilities

2.1 The Standard Bayesian Test

Suppose that for a given m and unknown $\theta \in (0, 1) \equiv \Theta$, a binomial random variable, $X_m \sim \mathcal{B}(m, \theta)$ with a *pmf* given by

$$p(x | \theta, m) = Pr(X_m = x | \theta, m) = \binom{m}{x} \theta^x (1 - \theta)^{m-x} \mathbf{I}[x = 0, 1, \dots, m].$$

We will see below that the structure of the hypotheses in (2) can generally be formulated as

$$H_0 : \theta \in \Theta_0 \quad \text{against} \quad H_1 : \theta \in \Theta_1 \quad (7)$$

for some $\Theta_0 \subset \Theta$ and $\Theta_1 = \Theta - \Theta_0$. We assume that given that the hypothesis H_i is true, θ has a proper prior pdf, $p_i(\cdot)$ over Θ_i , $i = 0, 1$, so that

$$\int_{\Theta_i} p_i(\theta) d\theta = 1, \quad i = 0, 1.$$

Accordingly, the test of the hypotheses in (7) can equivalently be formulated as the simple hypotheses concerning the marginal distribution of X_m , namely,

$$H_0 : X_m \sim f_{0,m}(x) \quad \text{against} \quad H_1 : X_m \sim f_{1,m}(x), \quad (8)$$

where for a given m and $i = 0, 1$, $f_{i,m}(\cdot)$ is the marginal distribution of X_m under H_i , given by

$$f_{i,m}(x) := \int_{\Theta_i} p(x | \theta, m) \times p_i(\theta) d\theta,$$

respectively. In the Bayesian framework, one typically assumes that the prior probability that H_0 is true, is $Pr(H_0) = \pi_0$ for some $0 < \pi_0 < 1$, and then proceeds to obtain the posterior probability of H_0 being true, **given** the data $\{X_m = x\}$, namely $Pr(H_0 | X_m = x)$, where, in the case of the hypotheses (8),

$$Pr(H_0 | X_m = x) = \frac{f_{0,m}(x)\pi_0}{f_{0,m}(x)\pi_0 + f_{1,m}(x)(1 - \pi_0)} = \frac{\ell \times B_m(x)}{1 + \ell \times B_m(x)}, \quad (9)$$

where we have substituted $\ell := \pi_0/(1 - \pi_0)$ and $B_m(x) := f_{0,m}(x)/f_{1,m}(x)$. The ratio $B_m(x)$, is the so-called Bayes factor of H_0 to H_1 (see, for example, Berger, Boukai, and Wang (1997)). Note that when $\pi_0 = 1/2$, so that $\ell \equiv 1$, which indicates that the prior probability of the null hypothesis is equal to the prior probability of the alternative hypothesis, the posterior probability of H_0 being true, given the data $\{X_m = x\}$ simplifies to

$$Pr(H_0 | X_m = x) = \frac{B_m(x)}{1 + B_m(x)}.$$

Hence, in this basic fixed-sample setup, the Bayesian would simply reject H_0 in favor of H_1 if $Pr(H_0 | X_m = x) < \pi_0 \equiv 1/2$ or equivalently, if $B_m(x) < 1$. That is, for a given m and $\ell = 1$, the Bayesian (fixed-sample) test is,

$$\text{Test}_{\text{Bayes}} := \begin{cases} \text{if } B_m(x) < 1 & \text{Reject } H_0 \text{ in (8)} \\ \text{if } B_m(x) \geq 1 & \text{Accept } H_0 \text{ in (8)}. \end{cases} \quad (10)$$

However, the Bayesian test in (10) might lead to certain ambiguities, especially whenever the value of the Bayes factor $B_m(x)$ is close to the boundary of 1. Based on Jeffreys (1961), Kass and Raftery (1995) suggestions of varying levels of 'rejection of H_0 ' all according to the amount of evidence in the data measured by the index $J_B = \log_{10}(B_m(x))$ are presented in Table 2.

Table 2: The values of Bayes factor B_m as a summary of the evidence provided by the data.

J_B	B_m	Evidence against H_0
-1/2 to 0	0.3162 to 1	Not worth more than a bare mention
-1 to -1/2	0.1 to 0.3162	Substantial
-2 to -1	0.01 to 0.1	Strong
< -2	< 0.01	Decisive

Accordingly, one would substantially reject H_0 if $-1 < J_B < -1/2$, and would strongly reject H_0 if $-2 < J_B < -1$ and decisively reject H_0 if $J_B < -2$.

As is apparent from (9), the calculations of the Bayes Factor require specification of the prior distribution for θ . For the binomial model in (7), a natural choice of prior distributions for θ would be the conjugate class of distributions over $\Theta = (0, 1)$, so that $\theta \sim \mathcal{Beta}(a, b)$ for some parameters $a > 0, b > 0$. Hence, the prior *pdf* of θ is given by

$$p(\theta) = \frac{\theta^{a-1}(1-\theta)^{b-1}}{\text{beta}(a, b)} \mathbf{I}[0 < \theta < 1],$$

where $\text{beta}(a, b) := \mathcal{I}_1(a, b)$, and where for any $\xi \in [0, 1]$,

$$\mathcal{I}_\xi(a, b) = \int_0^\xi u^{a-1}(1-u)^{b-1} du,$$

is the incomplete beta function. With this (conjugate) Beta prior distribution for θ over $\Theta = (0, 1)$, the posterior distribution of θ , given the data $X_m = x$, is the $\mathcal{Beta}(x+a, m-x+b)$ distribution, so that given m and $X_m = x$,

$$p(\theta | X_m) = \frac{\theta^{x+a-1}(1-\theta)^{m-x+b-1}}{\text{beta}(x+a, m-x+b)} \mathbf{I}[0 < \theta < 1]. \quad (11)$$

Further, in this case, the marginal probability distribution of X_m is the Beta-Binomial distribution, given by

$$f_m(x) = \Pr(X_m = x) = \binom{m}{x} \frac{\text{beta}(a+x, m-x+b)}{\text{beta}(a, b)} \mathbf{I}[x = 0, 1, \dots, m].$$

As an immediate application, consider the binomial experiment as summarized in Table 1 above, in which the sequential collection of the data was terminated after n observations according to the stopping rule in (3), so that for the given n and $\{S_n^Y = m\}$, $X_m \sim \mathcal{B}(m, \theta(\gamma))$, where, as in (6), $\theta \equiv \theta(\gamma) = \gamma/(z_0 + \gamma)$ with a known values z_0 . We remind the reader that according to the *Stopping Rule Principle* (SRP), posterior probabilities, as evidentiary data measures, remain unaffected by the optional stopping rule for the data collection, see Berger and Wolpert (1988, p. 74) or Berger (2013, p. 502). Hence, in this case too, with the stopping time M in (3), the expression (9) for the posterior probability of H_0 holds true also given the event $\mathcal{A}_{nm} := \{(M = n) \text{ and } (S_n^Y = m)\}$ for some $n \geq m$ and $m \in \{0, 1, 2, \dots\}$. That is

$$\Pr(H_0 | X_m = x, \mathcal{A}_{nm}) \equiv \Pr(H_0 | X_m = x) = \frac{\ell \times B_m(x)}{1 + \ell \times B_m(x)}.$$

In similarity to the hypotheses in (6), we consider two additional cases of hypotheses concerning the RR parameter γ . In all cases, we will assume equal prior probabilities of the null and the alternative hypotheses, so that, in all cases we take $\pi_0 = 1/2$ (so that $\ell = 1$) in (9).

Case 1: We are interested in testing of $H_0 : \gamma = 1$ against $H_1 : \gamma \neq 1$, which with $\theta_0 = (1 + z_0)^{-1}$, can readily be seen as equivalent to the testing of

$$H_0^{(1)} : \theta = \theta_0 \quad \text{against} \quad H_1^{(1)} : \theta \neq \theta_0. \quad (12)$$

In this case, for $x = 0, 1, \dots, m$, the marginal distributions of X_m under $H_0^{(1)}$ and $H_1^{(1)}$, are

$$f_{0,m}^{(1)}(x) = \binom{m}{x} \theta_0^x (1 - \theta_0)^{m-x}$$

and

$$f_{1,m}^{(1)}(x) = \binom{m}{x} \frac{\text{beta}(a+x, m-x+b)}{\text{beta}(a,b)},$$

respectively. Hence the Bayes factor of $H_0^{(1)}$ to $H_1^{(1)}$, in (12) is

$$B_m^{(1)}(x) = \frac{f_{0,m}^{(1)}(x)}{f_{1,m}^{(1)}(x)} = \frac{\text{beta}(a,b) \times \theta_0^x (1-\theta_0)^{m-x}}{\text{beta}(a+x, m-x+b)}. \quad (13)$$

Accordingly, upon termination of the observation process at $\{M = n\}$ for some n , with a given total number of observed side effects $\{S_n^Y = m\}$, of which $X_m = x$ of them are 'attributed' to treatment A , we may calculate the value of the Bayes Factor $B_m^{(1)}(x)$, in (13), for any choice of a, b and z_0 . Therefore, we can obtain the corresponding posterior probability of $H_0^{(1)}$ being true (given the data $\{X_m = x\}$), as given in (18) below.

Case 2: In a similar fashion, the testing of $H_0 : \gamma = 1$ against $H_1 : \gamma > 1$, which with $\theta_0 = (1+z_0)^{-1}$, can readily be seen as equivalent to the testing of

$$H_0^{(2)} : \theta = \theta_0 \quad \text{against} \quad H_1^{(2)} : \theta > \theta_0, \quad (14)$$

In this case too, with equal prior probabilities for $H_0^{(2)}$ and $H_1^{(2)}$, (i.e., $\pi_0 = 1/2$), we have for $x = 0, 1, \dots, m$,

$$f_{0,m}^{(2)}(x) = \binom{m}{x} \theta_0^x (1-\theta_0)^{m-x}$$

and

$$f_{1,m}^{(2)}(x) = \binom{m}{x} \frac{\text{beta}(a+x, m-x+b) - \mathcal{I}_{\theta_0}(a+x, m-x+b)}{\text{beta}(a,b)}.$$

Hence the Bayes factor of $H_0^{(2)}$ to $H_1^{(2)}$, in (14) is

$$B_m^{(2)}(x) = \frac{f_{0,m}^{(2)}(x)}{f_{1,m}^{(2)}(x)} = \frac{\text{beta}(a,b) \times \theta_0^x (1-\theta_0)^{m-x}}{\text{beta}(a+x, m-x+b) - \mathcal{I}_{\theta_0}(a+x, m-x+b)}. \quad (15)$$

Here too, upon termination of the observation process at $\{M = n\}$ for some n , with a given total number of observed side effects $\{S_n^Y = m\}$, of which $X_m = x$ of them are 'attributed' to treatment A , we may calculate the value of the Bayes Factor $B_m^{(2)}(x)$, in (15), for any choice of a, b and z_0 , and therefore obtain the corresponding posterior probability of $H_0^{(2)}$ being true (given the data $\{X_m = x\}$), as given in (18) below.

Case 3: Here we are testing $H_0 : \gamma \leq 1$ against $H_1 : \gamma > 1$, which is equivalent to testing of

$$H_0^{(3)} : \theta \leq \theta_0 \quad \text{against} \quad H_1^{(3)} : \theta > \theta_0, \quad (16)$$

with $\theta_0 = (1+z_0)^{-1}$. In this case too, with equal prior probabilities for $H_0^{(3)}$ and $H_1^{(3)}$, (i.e., $\pi_0 = 1/2$), we have for $x = 0, 1, \dots, m$,

$$f_{0,m}^{(3)}(x) = \binom{m}{x} \frac{\mathcal{I}_{\theta_0}(a+x, m-x+b)}{\text{beta}(a,b)}$$

and

$$f_{1,m}^{(3)}(x) = \binom{m}{x} \frac{\text{beta}(a+x, m-x+b) - \mathcal{I}_{\theta_0}(a+x, m-x+b)}{\text{beta}(a,b)}.$$

Hence the Bayes factor of $H_0^{(3)}$ to $H_1^{(3)}$, in (16) is

$$B_m^{(3)}(x) = \frac{f_{0,m}^{(3)}(x)}{f_{1,m}^{(3)}(x)} = \frac{\mathcal{I}_{\theta_0}(a+x, m-x+b)}{\text{beta}(a+x, m-x+b) - \mathcal{I}_{\theta_0}(a+x, m-x+b)}. \quad (17)$$

Clearly, the calculation of the posterior probability is straightforward as in the previous cases. In fact, in all Cases 1-3, we reject $H_0^{(i)}$ if $B_m^{(i)} < 1$, and report the respective posterior probabilities of $H_0^{(i)}$ and $H_1^{(i)}$, being true as

$$\alpha^* \left(B_m^{(i)}(x) \right) = \Pr \left(H_0^{(i)} \mid X_m = x \right) = \frac{B_m^{(i)}(x)}{1 + B_m^{(i)}(x)}, \quad \text{for } i = 1, 2, 3; \quad (18)$$

$$\beta^* \left(B_m^{(i)}(x) \right) = \Pr \left(H_1^{(i)} \mid X_m = x \right) = \frac{1}{1 + B_m^{(i)}(x)}, \quad \text{for } i = 1, 2, 3. \quad (19)$$

Accordingly, in all these three cases, the Bayesian test can be presented as,

$$\text{Test}_{\text{Bayes}} := \begin{cases} \text{if } B_m^{(i)}(x) < 1, & \text{Reject } H_0^{(i)} \text{ and report the} \\ & \text{posterior probability } \alpha^* \left(B_m^{(i)}(x) \right) \\ \text{if } B_m^{(i)}(x) \geq 1, & \text{Accept } H_0^{(i)} \text{ and report the} \\ & \text{posterior probability } \beta^* \left(B_m^{(i)}(x) \right), \end{cases} \quad (20)$$

for $i = 1, 2, 3$. Clearly, the Bayesian tests in (20) can incorporate Jeffrey's criteria as in Table 2 to determine the strength of the data in evidence to support the rejection of the respective $H_0^{(i)}$.

Note that to fully apply the test of the hypotheses in (8), one would need to specify the values of the prior distribution parameters a and b and matching allocation ratio between the two treatment groups, z_0 , in the calculations of $B_m^{(i)}(x)$, $i = 1, 2, 3$.

2.2 The Modified Bayesian Test

In the spirit of Table 2, we modify the standard Bayesian test to include a 'no-decision region'. This would often be a useful approach in the situation when there is an ambiguous result showing up.

As advocated and suggested in Berger, Boukai, and Wang (1997), we modify the Bayesian test in (8) to include a no-decision region in it. The modified Bayesian test has the form,

$$\text{Test}_{\text{M-Bayes}} := \begin{cases} \text{if } B_m(x) < r & \text{Reject } H_0 \text{ and report the conditional} \\ & \text{error probability } \alpha^* \left(B_m(x) \right) \\ \text{if } r \leq B_m(x) \leq a & \text{make no decision} \\ \text{if } B_m(x) > a & \text{Accept } H_0 \text{ and report the conditional} \\ & \text{error probability } \beta^* \left(B_m(x) \right), \end{cases} \quad (21)$$

where $r < a$ are two constants, defined and calculated as described in (22) below.

Let F_0 and F_1 be the *cdf* of $B_m(x)$ under H_0 and H_1 , respectively. Their inverse F_0^{-1} and F_1^{-1} exist over the range \mathcal{B} of $B_m(x)$. For any $b \in \mathcal{B}$, we let

$$\psi(b) := F_0^{-1}(1 - F_1(b)) \quad \text{and} \quad \psi^{-1}(b) := F_1^{-1}(1 - F_0(b)).$$

Accordingly, the decision constants r and a are calculated as,

$$\begin{aligned} r = 1 \quad \text{and} \quad a = \psi(1) \quad \text{if} \quad \psi(1) \geq 1, \\ r = \psi^{-1}(1) \quad \text{and} \quad a = 1 \quad \text{if} \quad \psi(1) < 1. \end{aligned} \tag{22}$$

As stated in Berger, Boukai, and Wang (1997), the posterior probabilities of H_0 and H_1 could also be interpreted as the conditional error frequentist Type I and Type II probabilities. $\text{Test}_{\text{M-Bayes}}$ is also a conditional frequentist test, arising from the use of the conditioning statistic

$$S(X) = \min\{B_m(X), \psi^{-1}(B_m(X))\}, \tag{23}$$

over the domain $\mathcal{X}^* = \{0 < S(X) < r\}$ (the complement of \mathcal{X}^* is the no-decision region). Therefore, based on (18) and (19), the conditional error probabilities upon accepting or rejecting which are in complete agreement with the Bayesian posterior probabilities are

$$\alpha^*(s) = \frac{s}{1+s} \quad \text{and} \quad \beta^*(s) = \frac{1}{1+\psi(s)}. \tag{24}$$

3 Example

Silva, Kulldorff, and Katherine Yih (2020) reported the results of a sequential study on the side effects of the H1N1 influenza vaccine during the 2009–2010 influenza season (see Lee et al. (2011)) which was conducted with equal allocation between the exposed group, A , and the not exposed group, B , so that study design matching constant is $z_0 = 1$ and hence, $\theta_0 = 1/2$. The 24 successive data points on (m, X_m) from the study cited there are presented in the table below along with the values of $\hat{\gamma} \equiv X_m/(m - X_m)$. Applying their iterative ‘sequential’ procedure to the hypotheses of Case 2, Silva, Kulldorff, and Katherine Yih (2020) have determined for $\alpha = 0.05$ that the testing procedure should have been terminated at the 19th-group data point, with $m = 222$ and $X_{222} = 134$, which resulted with estimated RR of $\hat{\gamma} = 1.5227$. For Case 3 and a related confidence interval, Silva and Zhuang (2022) have determined, for $\alpha = 0.1$, that the testing procedure should have been terminated at the 18th-group data point, with $m = 218$ and $X_{218} = 130$, which resulted with an estimated RR of $\hat{\gamma} = 1.4773$.

For comparison, we apply the above Bayesian Beta-Binomial models we propose to these 24 data points under several choices of prior distributions, however, all with prior mean of 0.5.

3.1 The Standard Bayesian Test

1) *Non-informative (uniform) prior distribution*

We assume a uniform prior distribution for θ , so that $\theta \sim \text{Beta}(a = 1, b = 1)$. We calculated the Bayes factor $B_m^{(i)}$ and the corresponding posterior probability $Pr(H_0^{(i)} | X_m = x)$, $i = 1, 2, 3$, for the hypotheses tests on the RR, γ , in the three cases we considered above. The numerical results are provided in Table 3 below.

As can be seen, for the hypotheses of Case 1 and Case 2, our Bayesian model above has led to the potentially earlier 'termination' at the 18th-group data point with a total of $m = 218$ 'events' of observed side effect of which $X_m = 130$ were noted in the treatment group with an estimated relative risk of $\hat{\gamma} = X_m/(m - X_m) = 1.4773$. The resulting Bayes Factors are $B_{218}^{(1)} = 0.2055$ and $B_{218}^{(2)} = 0.2059$, which are less than 0.3162 based on the standard shown in Table 2. This leads to a rejection of $H_0^{(i)}$, $i = 1, 2$ and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(1)} : \gamma = 1 \mid X_{218} = 130) = 0.1704, \quad \Pr(H_1^{(1)} : \gamma \neq 1 \mid X_{218} = 130) = 0.8296,$$

and

$$\Pr(H_0^{(2)} : \gamma = 1 \mid X_{218} = 130) = 0.1707, \quad \Pr(H_1^{(2)} : \gamma > 1 \mid X_{218} = 130) = 0.8293,$$

which are clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(i)}$, $i = 1, 2$, being true (marked in a red line in Figure 1).

On the other hand, for the hypotheses of Case 3, one would 'terminate' the observation process, much earlier, already at the 14th-group data point with a total of $m = 172$ 'events' of observed side effect of which $X_m = 91$ were noted in the treatment group, leading to the estimated relative risk of $\hat{\gamma} = 1.1235$. The resulting Bayes Factor is $B_{172}^{(3)} = 0.2880$ which are less than 0.3162 based on the standard shown in Table 2 and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(3)} : \gamma \leq 1 \mid X_{172} = 91) = 0.2236, \quad \Pr(H_1^{(3)} : \gamma > 1 \mid X_{172} = 91) = 0.7764,$$

which are clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(3)}$ being true (marked in a red line in Figure 1).

Remark 1. *We point out that in Case 3, we choose the early 'termination' at the 14th-group data point instead of 8th-group data point. At the 8th-group data point with a total of $m = 67$ 'events' of observed side effect of which $X_m = 34$ were noted in the treatment group, leading to the estimated relative risk of $\hat{\gamma} = X_m/(m - X_m) = 1.0303$. The resulting Bayes Factor is $B_{67}^{(3)} = 0.8241 < 1$, and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are*

$$\Pr(H_0^{(3)} : \gamma \leq 1 \mid X_{67} = 34) = 0.4518, \quad \Pr(H_1^{(3)} : \gamma > 1 \mid X_{67} = 34) = 0.5482.$$

*Although the value of $\Pr(H_0^{(3)} \mid X_{67} = 34)$ is less than 0.5, following the standard shown in Table 2, the evidence against $H_0^{(3)}$ at the 8th-group data point **does not worth more than a bare mention**. Therefore, we would substantially reject $H_0^{(3)}$ and stop at the 13th-group data point.*

Remark 2. *In Case 3, we observe that the values of Bayes Factor at the 4th and 9th-group data point are exactly equal to 1. Due to the data structure, we have the matching allocation ratio $z_0 = 1$ and at the 4th-group and 9th-group data points, $m - X_m = X_m$. Moreover, since the mean of the chosen prior distributions is 0.5, it is not surprising that at these two specific data points, the values of Bayes Factor are 1.*




Figure 1: The posterior probability of H_0 for the 24 data points of Table 3

Table 3: The values of Bayes factor and posterior probability of H_0 for each data point among the 3 different cases with the uniform prior.

Test	m	X_m	$\hat{\gamma}$	$B_m^{(1)}$	$\Pr(H_0^{(1)} X_m)$	$B_m^{(2)}$	$\Pr(H_0^{(2)} X_m)$	$B_m^{(3)}$	$\Pr(H_0^{(3)} X_m)$
1	12	1	0.0909	0.0381	0.0367	22.2857	0.9571	584.1429	0.9983
2	18	5	0.3846	0.6210	0.3831	19.5382	0.9513	30.4623	0.9682
3	24	11	0.8462	3.7195	0.7881	10.7807	0.9151	1.8984	0.6550
4	30	15	1.0000	4.4784	0.8175	8.9568	0.8996	1.0000	0.5000
5	34	15	0.7895	3.7811	0.7908	15.1377	0.9380	3.0035	0.7502
6	40	17	0.7391	3.3088	0.7679	18.9675	0.9499	4.7325	0.8256
7	46	20	0.7692	3.7458	0.7893	19.6273	0.9515	4.2398	0.8092
8	67	34	1.0303	6.5554	0.8676	11.9580	0.9228	0.8241	0.4518
9	78	39	1.0000	7.1142	0.8768	14.2285	0.9343	1.0000	0.5000
10	100	44	0.7857	3.9342	0.7973	33.8717	0.9713	7.6095	0.8838
11	115	51	0.7969	4.1504	0.8058	36.5229	0.9733	7.7999	0.8864
12	135	63	0.8750	6.9197	0.8737	31.4257	0.9692	3.5415	0.7798
13	167	88	1.1139	8.1376	0.8906	10.7609	0.9150	0.3224	0.2438
14	172	91	1.1235	7.8705	0.8873	10.1371	0.9102	0.2880	0.2236
15	190	107	1.2892	2.4347	0.7089	2.5390	0.7174	0.0429	0.0411
16	197	113	1.3452	1.3341	0.5716	1.3606	0.5764	0.0199	0.0195
17	211	124	1.4253	0.4531	0.3118	0.4556	0.3130	0.0055	0.0054
18	218	130	1.4773	0.2055	0.1704	0.2059	0.1707	0.0022	0.0022
19	222	134	1.5227	0.1003	0.0911	0.1004	0.0912	0.0010	0.0010
20	231	141	1.5667	0.0427	0.0410	0.0427	0.0410	0.0004	0.0004
21	240	148	1.6087	0.0175	0.0172	0.0175	0.0172	0.0001	0.0001
22	245	153	1.6630	0.0060	0.0060	0.0060	0.0060	0.0000	0.0000
23	247	155	1.6848	0.0039	0.0038	0.0039	0.0038	0.0000	0.0000
24	251	157	1.6702	0.0044	0.0044	0.0044	0.0044	0.0000	0.0000

We further applied Jeffrey's prior discussed in Jeffreys (1946), as a 'objective' and non-informative prior to above three cases. Specifically, for binomial model, the Jeffrey's prior is $Beta(1/2, 1/2)$. Since the results under the Jeffrey's prior are similar to the results we obtained under the uniform prior, we would not give detailed interpretation of the results under the Jeffrey's prior (shown in Appendix).

II) Informative prior distribution

Here we assume an informative prior distribution for θ that is induced by determining the values of

(a, b) by the following set of two equations,

$$E(\theta) = \frac{1}{1+z_0} \quad \text{and} \quad \Pr(|\gamma(\theta) - 1| \leq \epsilon \mid \theta) = \delta$$

for some given δ and ϵ , and where $\gamma(\theta) \equiv z_0 \times \theta / (1 - \theta)$ by (1). In the current example, we have $z_0 = 1$ and assume $\epsilon = 0.1$, and $\delta = 0.55$. Hence, we 'solve' for our prior parameters to obtain that $a = b = 113.8288$. Applying the procedure we proposed above, we calculated the Bayes factor $B_m^{(i)}$ and the corresponding posterior probability $\Pr(H_0^{(i)} \mid X_m = x)$, $i = 1, 2, 3$, for the hypotheses testing on γ in the three cases we considered above. The numerical results are provided in Table 4 below.

As can be seen, for the hypotheses of Case 1 and of Case 2, based on the standard shown in Table 2, our Bayesian model above has led to the potentially earlier 'termination' at the 17th-group data point with a total of $m = 211$ 'events' of observed side effect of which $X_m = 124$ were noted in the treatment group with an estimated relative risk of $\hat{\gamma} = 1.4253$. The resulting Bayes Factors are $B_{211}^{(1)} = 0.2901 < 0.3162$ and $B_{211}^{(2)} = 0.3017 < 0.3162$. This leads to a rejection of $H_0^{(i)}$, $i = 1, 2$, and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(1)} : \gamma = 1 \mid X_{211} = 124) = 0.2249, \quad \Pr(H_1^{(1)} : \gamma \neq 1 \mid X_{211} = 124) = 0.7751,$$

and

$$\Pr(H_0^{(2)} : \gamma = 1 \mid X_{211} = 124) = 0.2318, \quad \Pr(H_1^{(2)} : \gamma > 1 \mid X_{211} = 124) = 0.7682,$$

which are clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(i)}$, $i = 1, 2$, being true (marked in a red line in Figure 2).

Furthermore, for the hypotheses of Case 3, based on the standard shown in Table 2, the 15th-group data point with a total of $m = 190$ 'events' of observed side effect of which $X_m = 107$ were noted in the treatment group, leading to estimated relative risk of $\hat{\gamma} = 1.2892$. The resulting Bayes Factor is $B_{190}^{(3)} = 0.1361 < 0.3162$ and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(3)} : \gamma \leq 1 \mid X_{190} = 107) = 0.1198, \quad \Pr(H_1^{(3)} : \gamma > 1 \mid X_{190} = 107) = 0.8802,$$

which is clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(3)}$ being true (marked in red line in Figure 2).




Figure 2: The posterior probability of H_0 for the 24 data points of Table 4

Table 4: The values of Bayes factor and posterior probability of H_0 for each data point among different cases with the informative prior.

Test	m	X_m	$\hat{\gamma}$	$B_m^{(1)}$	$\Pr(H_0^{(1)} X_m)$	$B_m^{(2)}$	$\Pr(H_0^{(2)} X_m)$	$B_m^{(3)}$	$\Pr(H_0^{(3)} X_m)$
1	12	1	0.0909	0.8321	0.4542	3.2157	0.7628	2.8646	0.7412
2	18	5	0.3846	0.9115	0.4768	2.9928	0.7495	2.2834	0.6954
3	24	11	0.8462	1.0431	0.5106	2.3194	0.6987	1.2234	0.5502
4	30	15	1.0000	1.0640	0.5155	2.1280	0.6803	1.0000	0.5000
5	34	15	0.7895	1.0398	0.5098	2.5854	0.7211	1.4864	0.5978
6	40	17	0.7391	1.0137	0.5034	2.8419	0.7397	1.8036	0.6433
7	46	20	0.7692	1.0265	0.5065	2.8658	0.7413	1.7917	0.6418
8	67	34	1.0303	1.1360	0.5318	2.1710	0.6846	0.9111	0.4767
9	78	39	1.0000	1.1590	0.5368	2.3181	0.6986	1.0000	0.5000
10	100	44	0.7857	0.9627	0.4905	3.7991	0.7916	2.9465	0.7466
11	115	51	0.7969	0.9583	0.4894	3.9771	0.7991	3.1501	0.7590
12	135	63	0.8750	1.1289	0.5303	3.5494	0.7802	2.1442	0.6820
13	167	88	1.1139	1.1885	0.5431	1.7609	0.6378	0.4817	0.3251
14	172	91	1.1235	1.1693	0.5390	1.6904	0.6283	0.4456	0.3083
15	190	107	1.2892	0.6786	0.4043	0.7710	0.4354	0.1361	0.1198
16	197	113	1.3452	0.5061	0.3360	0.5497	0.3547	0.0862	0.0794
17	211	124	1.4253	0.2901	0.2249	0.3017	0.2318	0.0400	0.0384
18	218	130	1.4773	0.1920	0.1611	0.1966	0.1643	0.0237	0.0231
19	222	134	1.5227	0.1325	0.1170	0.1345	0.1185	0.0151	0.0149
20	231	141	1.5667	0.0824	0.0761	0.0831	0.0767	0.0086	0.0085
21	240	148	1.6087	0.0494	0.0471	0.0496	0.0473	0.0048	0.0047
22	245	153	1.6630	0.0276	0.0269	0.0277	0.0269	0.0025	0.0025
23	247	155	1.6848	0.0216	0.0212	0.0217	0.0212	0.0019	0.0019
24	251	157	1.6702	0.0225	0.0220	0.0225	0.0220	0.0020	0.0019

In conclusion, with the uniform prior, both Case 1 and Case 2 would reject and be 'terminated' at the 18th-group data point, and Case 3 would reject and be 'terminated' at the 14th-group data point. However, with the informative prior we chose, both Case 1 and Case 2 would reject and be 'terminated' at the 17th-group data point, and Case 3 would reject and be 'terminated' at the 15th-group data point.

3.2 The Modified Bayesian Test

Applying the modified Bayesian test in (21) to Case 1, 2, and 3 along with the same prior structures we discussed above, we analyze the results of the above example again. Under both types of the priors, we obtain the same conclusions that were obtained utilizing the standard Bayesian test for the hypotheses $H_0^{(i)}$, $i = 1, 2, 3$ (see Section 3.1). The results corresponding to the non-informative (uniform) prior distributions are shown in Figure 3, Table 5 and Table 6. The results corresponding to the informative prior distributions are shown in Figure 4, Table 7 and Table 8. However, under both prior structures, utilizing the modified Bayesian test, we see that there are several cases with some data points falling into the 'no-decision' region. In all cases, we provide the calculated conditional Type I and Type II error probabilities, α^* and β^* , corresponding to the 'Reject' or 'Accept' decision (see Table 6 and Table 8).

One may interpret the results of Case 2 under the informative prior case, for instance, as a guide for explaining the results shown in these 4 tables. According to the results in Table 7, at the 10th-group

data point, since the Bayes Factor $B_{100}^{(2)} = 3.7991$ is greater than $a^{(2)} = 3.5500$, one would accept the null hypothesis that the relative risk is equal to 1 and would report the corresponding conditional Type II error probability $\beta^* = 0.2136$ as shown in Table 8. On the other hand, at the 17th-group data point, since $B_{211}^{(2)} = 0.3017$ is less than $r^{(2)} = 1$, along with the standard mentioned in Table 2, we would reject the null hypothesis at the 17th-group data point and report the conditional Type I error probability $\alpha^* = 0.2318$. Additionally, there are some data points within 'no-decision' region since the Bayes Factor of the corresponding data point is within the values of $r^{(2)}$ and $a^{(2)}$.

I) *Non-informative (uniform) prior distribution*




Figure 3: The acceptance and rejection boundaries of B_m for the 24 data points of Table 5

Table 5: The values of Bayes factor and the boundaries based on it for each data point among different cases with the uniform prior.

Test	m	X_m	$\hat{\gamma}$	$B_m^{(1)}$	$r^{(1)}$	$a^{(1)}$	$B_m^{(2)}$	$r^{(2)}$	$a^{(2)}$	$B_m^{(3)}$	$r^{(3)}$	$a^{(3)}$
1	12	1	0.0909	0.0381	1	1.5710	22.2857	1	5.8652	584.1429	1	2.2226
2	18	5	0.3846	0.6210	1	2.3066	19.5382	1	4.6903	30.4623	1	1.9583
3	24	11	0.8462	3.7195	1	2.9225	10.7807	1	5.6789	1.8984	1	1.8080
4	30	15	1.0000	4.4784	1	2.4971	8.9568	1	6.5607	1.0000	1	1.7083
5	34	15	0.7895	3.7811	1	2.8358	15.1377	1	7.1038	3.0035	1	1.6586
6	40	17	0.7391	3.3088	1	3.3088	18.9675	1	5.7628	4.7325	0.6363	1
7	46	20	0.7692	3.7458	1	2.7747	19.6273	1	6.4415	4.2398	1	1.5532
8	67	34	1.0303	6.5554	1	3.6340	11.9580	1	7.5499	0.8241	1	1.1945
9	78	39	1.0000	7.1142	1	3.7717	14.2285	1	7.5508	1.0000	1	1.4105
10	100	44	0.7857	3.9342	1	3.9342	33.8717	1	7.4389	7.6095	1	1.3574
11	115	51	0.7969	4.1504	1	3.2564	36.5229	1	7.6064	7.7999	1	1.1485
12	135	63	0.8750	6.9197	1	4.0694	31.4257	1	7.2192	3.5415	1	1.1371
13	167	88	1.1139	8.1376	1	4.3758	10.7609	1	7.4343	0.3224	1	1.1233
14	172	91	1.1235	7.8705	1	4.1132	10.1371	1	8.4590	0.2880	1	1.2656
15	190	107	1.2892	2.4347	1	3.8676	2.5390	1	7.8237	0.0429	1	1.2517
16	197	113	1.3452	1.3341	1	3.6836	1.3606	1	7.4293	0.0199	1	1.1136
17	211	124	1.4253	0.4531	1	4.1037	0.4556	1	8.0592	0.0055	1	1.1098
18	218	130	1.4773	0.2055	1	3.9079	0.2059	1	7.6559	0.0022	0.8116	1
19	222	134	1.5227	0.1003	1	4.0227	0.1004	1	7.8268	0.0010	0.8131	1
20	231	141	1.5667	0.0427	1	3.8834	0.0427	1	7.5158	0.0004	1	1.1049
21	240	148	1.6087	0.0175	1	4.5363	0.0175	1	8.5869	0.0001	0.8193	1
22	245	153	1.6630	0.0060	1	4.2679	0.0060	1	8.0842	0.0000	1	1.1018
23	247	155	1.6848	0.0039	1	4.3227	0.0039	1	8.1648	0.0000	1	1.1014
24	251	157	1.6702	0.0044	1	4.4320	0.0044	1	8.3256	0.0000	1	1.1006

Table 6: The decision and corresponding conditional α^* and β^* for each data point among different cases with the uniform prior. (Decision: 'R' indicates Reject, 'A' indicates Accept, 'ND' indicates No Decision, 'NA' indicates No Answer.)

Test	$\hat{\gamma}$	$B_m^{(1)}$	Decision	α^* (or β^*)	$B_m^{(2)}$	Decision	α^* (or β^*)	$B_m^{(3)}$	Decision	α^* (or β^*)
1	0.0909	0.0381	R	0.0367	22.2857	A	0.0441	584.1429	A	0.0016
2	0.3846	0.6210	R	0.3831	19.5382	A	0.0491	30.4623	A	0.0261
3	0.8462	3.7195	A	0.2145	10.7807	A	0.0926	1.8984	A	0.3313
4	1.0000	4.4784	A	0.1841	8.9568	A	0.1072	1.0000	ND	NA
5	0.7895	3.7811	A	0.2145	15.1377	A	0.0621	3.0035	A	0.2460
6	0.7391	3.3088	ND	NA	18.9675	A	0.0551	4.7325	A	0.1742
7	0.7692	3.7458	A	0.2145	19.6273	A	0.0491	4.2398	A	0.1742
8	1.0303	6.5554	A	0.1391	11.9580	A	0.0805	0.8241	R	0.4518
9	1.0000	7.1142	A	0.1391	14.2285	A	0.0705	1.0000	ND	NA
10	0.7857	3.9342	ND	NA	33.8717	A	0.0303	7.6095	A	0.1173
11	0.7969	4.1504	A	0.2145	36.5229	A	0.0279	7.7999	A	0.0944
12	0.8750	6.9197	A	0.1391	31.4257	A	0.0330	3.5415	A	0.2082
13	1.1139	8.1376	A	0.1098	10.7609	A	0.0926	0.3224	R	0.2438
14	1.1235	7.8705	A	0.1228	10.1371	A	0.0926	0.2880	R	0.2236
15	1.2892	2.4347	ND	NA	2.5390	ND	NA	0.0429	R	0.0411
16	1.3452	1.3341	ND	NA	1.3606	ND	NA	0.0199	R	0.0195
17	1.4253	0.4531	R	0.3118	0.4556	R	0.3130	0.0055	R	0.0055
18	1.4773	0.2055	R	0.1705	0.2059	R	0.1707	0.0022	R	0.0022
19	1.5227	0.1003	R	0.0912	0.1004	R	0.0912	0.0010	R	0.0010
20	1.5667	0.0427	R	0.0410	0.0427	R	0.0410	0.0004	R	0.0004
21	1.6087	0.0175	R	0.0172	0.0175	R	0.0172	0.0001	R	0.0001
22	1.6630	0.0060	R	0.0060	0.0060	R	0.0060	0.0000	R	0.0000
23	1.6848	0.0039	R	0.0039	0.0039	R	0.0039	0.0000	R	0.0000
24	1.6702	0.0044	R	0.0044	0.0044	R	0.0044	0.0000	R	0.0000

II) *Informative prior distribution*




Figure 4: The acceptance and rejection boundaries of B_m for the 24 data points of Table 7

Table 7: The values of Bayes factor and the decision based on it for each data point among different cases with the informative prior.

Test	m	X_m	$\hat{\gamma}$	$B_m^{(1)}$	$r^{(1)}$	$a^{(1)}$	$B_m^{(2)}$	$r^{(2)}$	$a^{(2)}$	$B_m^{(3)}$	$r^{(3)}$	$a^{(3)}$
1	12	1	0.0909	0.8321	1	1.0175	3.2157	1	3.2157	2.8646	0.9138	1
2	18	5	0.3846	0.9115	1	1.0304	2.9928	1	3.2401	2.2834	0.9091	1
3	24	11	0.8462	1.0431	1	1.0431	2.3194	1	3.5175	1.2234	0.9050	1
4	30	15	1.0000	1.0640	1	1.0557	2.1280	1	3.5410	1.0000	0.9020	1
5	34	15	0.7895	1.0398	1	1.0640	2.5854	1	3.3040	1.4864	0.9010	1
6	40	17	0.7391	1.0137	1	1.0764	2.8419	1	3.3275	1.8036	0.8988	1
7	46	20	0.7692	1.0265	1	1.0649	2.8658	1	3.3507	1.7917	0.8980	1
8	67	34	1.0303	1.1360	1	1.0905	2.1710	1	3.3071	0.9111	1	1.0337
9	78	39	1.0000	1.1590	1	1.1290	2.3181	1	3.4708	1.0000	0.8943	1
10	100	44	0.7857	0.9627	1	1.1711	3.7991	1	3.5500	2.9465	0.8940	1
11	115	51	0.7969	0.9583	1	1.1832	3.9771	1	3.4806	3.1501	1	1.0379
12	135	63	0.8750	1.1289	1	1.1799	3.5494	1	3.5494	2.1442	1	1.0384
13	167	88	1.1139	1.1885	1	1.2378	1.7609	1	3.8995	0.4817	1	1.0395
14	172	91	1.1235	1.1693	1	1.2671	1.6904	1	3.5525	0.4456	0.8962	1
15	190	107	1.2892	0.6786	1	1.2550	0.7710	1	3.8506	0.1361	1	1.1207
16	197	113	1.3452	0.5061	1	1.2897	0.5497	1	3.7520	0.0862	1	1.0403
17	211	124	1.4253	0.2901	1	1.2661	0.3017	1	3.5590	0.0400	1	1.0404
18	218	130	1.4773	0.1920	1	1.3027	0.1966	1	3.6984	0.0237	1	1.1186
19	222	134	1.5227	0.1325	1	1.3094	0.1345	1	3.7108	0.0151	0.8981	1
20	231	141	1.5667	0.0824	1	1.2999	0.0831	1	3.8571	0.0086	1	1.0403
21	240	148	1.6087	0.0494	1	1.3390	0.0496	1	4.0043	0.0048	1	1.1172
22	245	153	1.6630	0.0276	1	1.3231	0.0277	1	3.6634	0.0025	1	1.0404
23	247	155	1.6848	0.0216	1	1.3264	0.0217	1	3.6694	0.0019	1	1.0404
24	251	157	1.6702	0.0225	1	1.3329	0.0225	1	3.6814	0.0020	1	1.0406

Table 8: The decision and corresponding conditional α^* and β^* for each data point among different cases with the informative prior. (Decision: 'R' indicates Reject, 'A' indicates Accept, 'ND' indicates No Decision, 'NA' indicates No Answer.)

Test	$\hat{\gamma}$	$B_m^{(1)}$	Decision	α^* (or β^*)	$B_m^{(2)}$	Decision	α^* (or β^*)	$B_m^{(3)}$	Decision	α^* (or β^*)
1	0.0909	0.8321	R	0.4542	3.2157	ND	NA	2.8646	A	0.2610
2	0.3846	0.9115	R	0.4769	2.9928	ND	NA	2.2834	A	0.2903
3	0.8462	1.0431	ND	NA	2.3194	ND	NA	1.2234	A	0.4549
4	1.0000	1.0640	A	0.4287	2.1280	ND	NA	1.0000	ND	NA
5	0.7895	1.0398	ND	NA	2.5854	ND	NA	1.4864	A	0.3862
6	0.7391	1.0137	ND	NA	2.8419	ND	NA	1.8036	A	0.3530
7	0.7692	1.0265	ND	NA	2.8658	ND	NA	1.7917	A	0.3530
8	1.0303	1.1360	A	0.4389	2.1710	ND	NA	0.9111	R	0.4767
9	1.0000	1.1590	A	0.4389	2.3181	ND	NA	1.0000	ND	NA
10	0.7857	0.9627	R	0.4905	3.7991	A	0.2136	2.9465	A	0.2610
11	0.7969	0.9583	R	0.4894	3.9771	A	0.2034	3.1501	A	0.2334
12	0.8750	1.1289	ND	NA	3.5494	ND	NA	2.1442	A	0.3210
13	1.1139	1.1885	ND	NA	1.7609	ND	NA	0.4817	R	0.3251
14	1.1235	1.1693	ND	NA	1.6904	ND	NA	0.4456	R	0.3082
15	1.2892	0.6786	R	0.4043	0.7710	R	0.4353	0.1361	R	0.1198
16	1.3452	0.5061	R	0.3360	0.5497	R	0.3547	0.0862	R	0.0794
17	1.4253	0.2901	R	0.2249	0.3017	R	0.2318	0.0400	R	0.0385
18	1.4773	0.1920	R	0.1611	0.1966	R	0.1643	0.0237	R	0.0232
19	1.5227	0.1325	R	0.1170	0.1345	R	0.1186	0.0151	R	0.0149
20	1.5667	0.0824	R	0.0761	0.0831	R	0.0767	0.0086	R	0.0085
21	1.6087	0.0494	R	0.0471	0.0496	R	0.0473	0.0048	R	0.0048
22	1.6630	0.0276	R	0.0269	0.0277	R	0.0270	0.0025	R	0.0025
23	1.6848	0.0216	R	0.0211	0.0217	R	0.0212	0.0019	R	0.0019
24	1.6702	0.0225	R	0.0220	0.0225	R	0.0220	0.0020	R	0.0020

3.3 HPD Region

Once the 'termination' point of the study is known (with a given prior distribution), it is possible to obtain the $(1 - c) \times 100\%$ Highest Posterior Density (HPD) region for the RR, γ , as now one has available its posterior *pdf* given the data. We illustrate this by calculating a 95% HPD region for each 'terminated' data point we discuss above.

- **Case 1** ($H_0^{(1)} : \gamma = 1$ against $H_1^{(1)} : \gamma \neq 1$) & **Case 2** ($H_0^{(2)} : \gamma = 1$ against $H_1^{(2)} : \gamma > 1$):

At the 18th-group data point, which is the 'terminated' data point for Case 1 and Case 2 with the uniform prior, we obtain the posterior distribution of $\theta \mid X_{218} \sim \text{Beta}(131, 89)$ where $X_{218} = 130$. The calculated 95% HPD region of θ is (0.5305, 0.6599) shown in Figure 5, which indicates the corresponding 95% HPD region of γ , the Relative Risk, is (1.1298, 1.9407). Notice that the conditional Type I error probability is 0.1705 for Case 1 and is 0.1707 for Case 2 under the modified Bayesian test. Although the 95% HPD region excludes $\gamma = 1$, the conditional Type I error probabilities indicate there are around 17% in favor of the null hypothesis for Case 1 and 2.




Figure 5: The 95% HPD region of $\theta \mid X_{218} \sim \mathcal{Beta}(131, 89)$ where $X_{218} = 130$ at 18th-group data point with the posterior *pdf* of $\theta \mid X_{218}$.

At the 17th-group data point, which is the 'terminated' data point for Case 1 and Case 2 with the informative prior, we obtain the posterior distribution of $\theta \mid X_{211} \sim \mathcal{Beta}(237.8288, 200.8288)$ where $X_{211} = 124$. The calculated 95% HPD region of θ is (0.4955, 0.5888) which indicates the corresponding 95% HPD region of γ is (0.9820, 1.4318). Notice that the conditional Type I error probability is 0.2249 for Case 1 and is 0.2318 for Case 2 under the modified Bayesian test.

• **Case 3** ($H_0^{(3)} : \gamma \leq 1$ against $H_1^{(3)} : \gamma > 1$):

At the 14th-group data point, which is the 'terminated' data point for Case 3 with the uniform prior, we obtain the posterior distribution of $\theta \mid X_{172} \sim \mathcal{Beta}(92, 82)$ where $X_{172} = 91$. The calculated 95% HPD region of θ is (0.4546, 0.6027) which indicates the corresponding 95% HPD region of γ is (0.8336, 1.5168). The conditional Type I error probability is 0.2236 under the modified Bayesian test.

At the 15th-group data point, which is the 'terminated' data point for Case 3 with the informative prior, we obtain the posterior distribution of $\theta \mid X_{190} \sim \mathcal{Beta}(220.8288, 196.8288)$ where $X_{190} = 107$. The calculated 95% HPD region of θ is (0.4809, 0.5765) which indicates the corresponding 95% HPD region of γ is (0.9263, 1.3613). The conditional Type I error probability is 0.1198 under the modified Bayesian test.

Remark 3. *We notice that some 95% HPD regions may include $\gamma = 1$, the value of γ under the null hypothesis. Since the Bayes Factor shows that the overall evidence from the data favors the alternative compared to the null, the 95% HPD region reflects that the null is not entirely implausible. Even if the null value is within the 95% HPD region, the posterior may still assign higher credibility to other values (those outside the null), which explains why the Bayes Factor rejects the null. Hence, the null hypothesis may still be within a credible interval, but its likelihood is overshadowed by the alternative. It also indicates that the null hypothesis is rejected substantially.*

3.4 Connection to the UMPBT

Johnson (2013) has introduced the new concept of the Uniformly Most Powerful Bayesian Test (UMPBT) and proved its existence in Nikooienejad and Johnson (2021). Considering Case 2, now treated as the UMPBT, we construct the corresponding 'group' sequential Bayesian test with a certain 'termination' point. However, we note that in the current context, the threshold of the

Bayes Factor B_m to reject the null hypothesis is of the form $B_m < 1/\lambda$ for some $\lambda > 0$. By Lemma 1 in Johnson (2013), the UMPBT($1/\lambda$) is constructed by finding θ_1 that $\theta_1 > \theta_0$ and

$$\theta_1 = \arg \min_{\theta} \frac{\ln(1/\lambda) - m [\ln(1 - \theta) - \ln(1 - \theta_0)]}{\ln[\theta/(1 - \theta)] - \ln[\theta_0/(1 - \theta_0)]},$$

which can be solved numerically. For instance, by applying the suggestion of the Jeffrey's evidence level shown in Table 2, we may reject the null hypothesis if $B_m < 0.3162$, so that $1/\lambda = 0.3162$ in this case.

I) *Non-informative (uniform) prior distribution*

Since the 'termination' point of Case 2 with the uniform prior is the 18th-group data point, we have $B_{218} = 0.2059$ and $\Pr(H_0^{(2)} | X_{218} = 130) = 0.1707$, $m = 218$ and $X_m = 130$. We use $1/\lambda = 0.2059$ and obtain the corresponding $\theta_1 = 0.5601$. At this value of θ_1 and $\theta_0 = 0.5$, $B_m < 1/\lambda$ whenever 123 or more of the $n = 218$ patients enrolled in this fixed sample size study. Accordingly, for the fixed sample size test (with $n = 218$), once the number of the observed side effect $X_n \geq 123$, we would reject the null hypothesis, incurring a (classical) Type I error probability $\alpha = P_{\theta_0}(X_n \geq 123) = 0.0336$. This rejection region for this 3.36% significance test also corresponds to the region for which the Bayes Factor corresponding to the UMPBT($1/\lambda$) for all values of $1/\lambda \in (0.166, 0.2114)$. With equal prior probabilities of the null and the alternative hypotheses we assumed previously ($\ell = 1$), the implied significant level of 0.0336 for this UMPBT which approximately corresponds to the Bayesian test resulting with

$$0.1424 < \Pr(H_0^{(2)} | Data) < 0.1745.$$

This serves as illustration to the fact that unlike the posterior probabilities, the p-value or attained significant level, is not a true measure of the strength of the evidence in favor/against the null hypothesis, see Sellke, Bayarri, and Berger (2001) for a discussion of this point.

However, note that, if we choose Jeffrey's evidence level of $1/\lambda = 0.3162$, the calculated $B_{218} = 0.2059$ and $\Pr(H_0^{(2)} | X_{218} = 130) = 0.1707$ which would not match the results obtained from the UMPBT procedure in this case. This may be attributed to the group sequential nature of the data and the uniform prior that we considered here.

II) *Informative prior distribution*

Since the 'termination' point of Case 2 with the informative prior is the 17th-group data point, we have $B_{211} = 0.3017$ and $\Pr(H_0^{(2)} | X_{211} = 124) = 0.2318$, $m = 211$ and $X_m = 124$. Applying Jeffrey's evidence level of $1/\lambda = 0.3162$, with the corresponding (equivalent) fixed sample size of this UMPBT $n = 211$, we obtain the corresponding $\theta_1 = 0.5522$. With this value of θ_1 and $\theta_0 = 0.5$, $B_m < 1/\lambda$ whenever 117 or more of the $n = 211$ patients enrolled in this fixed sample size study. Accordingly, for the fixed sample size test, once the number of the observed side effect $X_n \geq 117$, we would reject the null hypothesis, incurring a (classical) Type I error $\alpha = P_{\theta_0}(X_n \geq 117) = 0.0648$. This rejection region for this 6.48% significance test also corresponds to the region for which the Bayes Factor corresponding to the UMPBT($1/\lambda$) for all values of $1/\lambda \in (0.2854, 0.3520)$. With equal prior probabilities of the null and the alternative hypotheses we assumed previously ($\ell = 1$), the implied significant level of 0.0648 for this UMPBT which approximately corresponds to the Bayesian test resulting with

$$0.2221 < \Pr(H_0^{(2)} | Data) < 0.2603.$$

4 Summary and Discussion

In this paper, we propose the standard Bayesian test and the modified Bayesian test of hypotheses concerning the Relative Risk, γ , of a two-arm clinical trial. In this context, the Relative Risk γ can be represented as $\theta(\gamma)$, a parameter representing an event probability. Since the output of each observation collected is binary data, the sequential experimental process can be viewed as a sequential binomial process with probability $\theta(\gamma)$. Note that, under the Bayesian framework, based on the SRP, each data point remains unaffected by the optimal stopping rule used in the process (unlike the 'classical' sequential test). Within the Bayesian framework, we consider the sequential testing of hypotheses concerning the parameter $\theta(\gamma)$. By utilizing the conjugate beta-binomial model, we are able to obtain the corresponding decision 'rule' for the test at each observed data point as determined from the calculated value of the Bayes Factor.

To deal with the values of the Bayes Factor that are too close to the decision boundaries, Jefferey's criteria for evidentiary level for a 'rejection of H_0 ' are taken into consideration. Additionally, we consider a modification of the standard Bayesian test (Berger, Boukai, and Wang (1997)) which includes a 'no-decision' region and calculate corresponding conditional Type I and Type II error probabilities α^* and β^* . To illustrate our approach and the methods discussed, we analyze the data presented in Silva, Kulldorff, and Katherine Yih (2020) under the three different hypothesis testing cases, and under several different priors. It is worth pointing out that the informative prior we proposed is designed to use the knowledge of the bounded-width probability. For each case with a different priors, we analyze the calculated Bayes Factor corresponding to each data point and make the decision within two Bayesian tests.

Specifically, we consider in Case 2 the very same hypothesis testing problem as shown in Silva, Kulldorff, and Katherine Yih (2020). The result presented in Silva, Kulldorff, and Katherine Yih (2020) indicated that the testing procedure should have been terminated at the 19th-group data point. However, the results obtained from both the standard Bayesian test and the modified Bayesian test lead to a potentially earlier 'termination' at the 18th-group data point under the uniform prior and at the 17th-group data point under an informative prior. Furthermore, utilizing the modified Bayesian test with a uniform prior, at the 18th-group data point, the Type I error conditional probability is $\alpha^* = 0.1707$ (given the data). Similarly, with the modified Bayesian test and under an informative prior, at the 17th-group data point, the conditional Type I error probability is $\alpha^* = 0.2318$ (given the data). From Section 3.4, we find our 'termination' based on the Bayesian test with a uniform prior corresponding to a p-value of 0.0336 and with an informative prior corresponding to a p-value of 0.0648 from the frequentist point of view.

Case 3 has the very same hypothesis testing problem as shown in Silva and Zhuang (2022). The result presented in Silva and Zhuang (2022) indicated that the testing procedure should have been terminated at the 18th-group data point. However, the results obtained from both the standard Bayesian test and the modified Bayesian test lead to the potentially earlier 'termination' at the 14th-group data point with a uniform prior and at the 15th-group data point with an informative prior. Furthermore, with the modified Bayesian test under a uniform prior, at the 14th-group data point, the conditional Type I error probability $\alpha^* = 0.2236$ (given the data). Similarly, with the modified Bayesian test under an informative prior, at the 15th-group data point, the conditional Type I error probability $\alpha^* = 0.1198$ (given the data).

These cases illustrate the benefits of Bayesian testing in this context. Unlike the classical sequential test, which typically requires heavy calculations to determine 'stopping boundaries' as well as 'deci-

sion boundaries' (for a-priory specified Type I and Type II error probabilities), the Bayesian test is easy to use and implement, and it could obtain the test results in a relatively simple manner. Compared with the results obtained in Silva, Kulldorff, and Katherine Yih (2020) and Silva and Zhuang (2022), we would conclude that our results are consistent with their results. Although our decisions for Case 2 and Case 3 arrive slightly earlier than theirs, the values of the data points are similar. In addition, we are able to illustrate, using the very same data, the connection of our Bayesian test and the UMPBT. With this connection, the results we obtained from the Bayesian test can be approximately interpreted by the rejection region and the p-value from the frequentist perspective of the UMP. Moreover, by applying modified Bayesian test, we could even obtain conditional error probabilities as well, which give us a measure of the data evidence in making decisions (of 'Reject' H_0 or 'Accept' H_0). Indeed, for such binary data hypothesis testing, utilizing Bayesian framework could provide a straightforward and easy path to analyze the data.

References

- [1] Harold Jeffreys. "An invariant form for the prior probability in estimation problems". *Proceedings of the Royal Society of London. Series A. Mathematical and Physical Sciences* 186.1007 (1946), pp. 453–461.
- [2] H Jeffreys. *edition 3. Theory of probability*. 1961.
- [3] James O Berger and Robert L Wolpert. "The likelihood principle". IMS. 1988.
- [4] Robert E Kass and Adrian E Raftery. "Bayes factors". *Journal of the american statistical association* 90.430 (1995), pp. 773–795.
- [5] James O Berger, Ben Boukai, and Jinping Wang. "Unified frequentist and Bayesian testing of a precise hypothesis". *Statistical Science* 12.3 (1997), pp. 133–160.
- [6] Thomas Sellke, María Jesús Bayarri, and James O Berger. "Calibration of ρ values for testing precise null hypotheses". *The American Statistician* 55.1 (2001), pp. 62–71.
- [7] Martin Kulldorff et al. "A maximized sequential probability ratio test for drug and vaccine safety surveillance". *Sequential analysis* 30.1 (2011), pp. 58–78.
- [8] Grace M Lee et al. "H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project". *American journal of preventive medicine* 41.2 (2011), pp. 121–128.
- [9] James O Berger. *Statistical decision theory and Bayesian analysis*. Springer Science & Business Media, 2013.
- [10] Valen E Johnson. "Uniformly most powerful Bayesian tests". *Annals of statistics* 41.4 (2013), p. 1716.
- [11] Ivair R Silva, Martin Kulldorff, and W Katherine Yih. "Optimal alpha spending for sequential analysis with binomial data". *Journal of the Royal Statistical Society Series B: Statistical Methodology* 82.4 (2020), pp. 1141–1164.
- [12] Amir Nikooienejad and Valen E Johnson. "On the existence of uniformly most powerful bayesian tests with application to non-central chi-squared tests". *Bayesian analysis* 16.1 (2021), p. 93.
- [13] Ivair R. Silva, Judith Maro, and Martin Kulldorff. "Exact sequential test for clinical trials and post-market drug and vaccine safety surveillance with Poisson and binary data". *Statistics in Medicine* 40.22 (2021), pp. 4890–4913.

- [14] Ivair R Silva and Yan Zhuang. “Bounded-width confidence interval following optimal sequential analysis of adverse events with binary data”. *Statistical Methods in Medical Research* 31.12 (2022), pp. 2323–2337.
- [15] Jiayue Wang and Ben Boukai. “Early Detection of Treatment’s Side Effect: A Sequential Approach”. *Available at SSRN 4704084* (2024).

5 Appendix

In this section, we present the results obtained from the standard Bayesian test and the modified Bayesian test under the Jeffrey’s (non-informative) prior of the data from Silva, Kulldorff, and Katherine Yih (2020).

5.1 The Standard Bayesian Test

Introduced in Jeffreys (1946), the Jeffrey’s prior as considered an ‘objective’ or non-informative prior distribution is $Beta \sim (1/2, 1/2)$ for binomial distribution in our case. We calculated the Bayes factor $B_m^{(i)}$ and the corresponding posterior probability $Pr(H_0^{(i)} | X_m = x)$, $i = 1, 2, 3$, for the hypotheses tests on the RR, γ , in the three cases we considered. The numerical results are provided in Table 9 below.

As can be seen, for the hypotheses of Case 1, our Bayesian model has led to the potentially earlier ‘termination’ at the 18th-group data point with a total of $m = 218$ ‘events’ of observed side effect of which $X_m = 130$ were noted in the treatment group with an estimated relative risk of $\hat{\gamma} = X_m/(m - X_m) = 1.4773$. The resulting Bayes Factor is $B_{218}^{(1)} = 0.3160$, which is less than 0.3162 based on the standard shown in Table 2. This leads to a rejection of $H_0^{(1)}$ and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(1)} : \gamma = 1 | X_{218} = 130) = 0.2401 \quad \Pr(H_1^{(1)} : \gamma \neq 1 | X_{218} = 130) = 0.7599,$$

which are clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(1)}$ being true (marked in a red line in Figure 6).

For the hypotheses of Case 2, one would ‘terminate’ the observation process at the 19th-group data point with a total of $m = 222$ ‘events’ of observed side effect of which $X_m = 134$ were noted in the treatment group, leading to the estimated relative risk of $\hat{\gamma} = X_m/(m - X_m) = 1.4253$. The resulting Bayes Factors are $B_{222}^{(2)} = 0.1539$ which are less than 0.3162 based on the standard shown in Table 2 and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(2)} : \gamma \leq 1 | X_{222} = 134) = 0.1334 \quad \text{and} \quad \Pr(H_1^{(2)} : \gamma > 1 | X_{222} = 134) = 0.8666,$$

which are clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(2)}$ being true (marked in a red line in Figure 6).

On the other hand, for the hypotheses of Case 3, the observation process would ‘terminate’ much earlier at the 14th-group data point with a total of $m = 172$ ‘events’ of observed side effect of which $X_m = 91$ were noted in the treatment group, leading to the estimated relative risk of $\hat{\gamma} =$

$X_m/(m - X_m) = 1.1235$. The resulting Bayes Factor is $B_{172}^{(3)} = 0.2869$ which are less than 0.3162 based on the standard shown in Table 2 and the posterior probabilities of the null hypothesis and the alternative hypothesis given the data are

$$\Pr(H_0^{(3)} : \gamma \leq 1 \mid X_{172} = 91) = 0.2229 \quad \text{and} \quad \Pr(H_1^{(3)} : \gamma > 1 \mid X_{172} = 91) = 0.7771,$$

which are clearly smaller than the assumed prior probability $\pi_0 = 0.5$ of $H_0^{(3)}$ being true (marked in a red line in Figure 6).




Figure 6: The posterior probability of H_0 for the 24 data points of Table 9

Table 9: The values of Bayes factor and posterior probability of H_0 for each data point among the 3 different cases with the Jeffrey's prior.

Test	m	X_m	$\hat{\gamma}$	$B_m^{(1)}$	$\Pr(H_0^{(1)} \mid X_m)$	$B_m^{(2)}$	$\Pr(H_0^{(2)} \mid X_m)$	$B_m^{(3)}$	$\Pr(H_0^{(3)} \mid X_m)$
1	12	1	0.0909	0.0348	0.0337	34.7839	0.9721	997.4399	0.9990
2	18	5	0.3846	0.8570	0.4615	30.4686	0.9682	34.5543	0.9719
3	24	11	0.8462	5.7079	0.8509	16.6892	0.9435	1.9239	0.6580
4	30	15	1.0000	6.9221	0.8738	13.8442	0.9326	1.0000	0.5000
5	34	15	0.7895	5.8156	0.8533	23.5774	0.9593	3.0541	0.7533
6	40	17	0.7391	5.0778	0.8355	29.6152	0.9673	4.8323	0.8285
7	46	20	0.7692	5.7730	0.8524	30.6617	0.9684	4.3113	0.8117
8	67	34	1.0303	10.2206	0.9109	18.6318	0.9491	0.8230	0.4514
9	78	39	1.0000	11.1045	0.9174	22.2090	0.9569	1.0000	0.5000
10	100	44	0.7857	6.1053	0.8593	53.0962	0.9815	7.6967	0.8850
11	115	51	0.7969	6.4501	0.8658	57.2681	0.9828	7.8787	0.8874
12	135	63	0.8750	10.8056	0.9153	49.2625	0.9801	3.5590	0.7807
13	167	88	1.1139	12.7261	0.9271	16.8142	0.9439	0.3212	0.2431
14	172	91	1.1235	12.3066	0.9248	15.8372	0.9406	0.2869	0.2229
15	190	107	1.2892	3.7840	0.7910	3.9445	0.7978	0.0424	0.0407
16	197	113	1.3452	2.0676	0.6740	2.1082	0.6783	0.0196	0.0193
17	211	124	1.4253	0.6991	0.4114	0.7028	0.4127	0.0054	0.0053
18	218	130	1.4773	0.3160	0.2401	0.3167	0.2405	0.0022	0.0022
19	222	134	1.5227	0.1538	0.1333	0.1539	0.1334	0.0010	0.0010
20	231	141	1.5667	0.0653	0.0613	0.0653	0.0613	0.0004	0.0004
21	240	148	1.6087	0.0266	0.0259	0.0266	0.0259	0.0001	0.0001
22	245	153	1.6630	0.0091	0.0090	0.0091	0.0090	0.0000	0.0000
23	247	155	1.6848	0.0058	0.0058	0.0058	0.0058	0.0000	0.0000
24	251	157	1.6702	0.0067	0.0067	0.0067	0.0067	0.0000	0.0000

In conclusion, under the Jeffrey's prior, Case 1 would reject and be 'terminated' at the 18th-group data point, Case 2 would reject and 'terminated' at the 19th-group data point, and Case 3 would reject and 'terminated' at the 14th-group data point.

5.2 The modified Bayesian Test

In the modified Bayesian Sequential test, we obtain the same conclusions that were obtained utilizing the standard Bayesian test for the hypotheses $H_0^{(i)}$, $i = 1, 2, 3$ (see Section 5.1). The results corresponding to the Jeffrey's prior distribution are shown in Figure 7, Table 10 and Table 11. The calculated conditional Type I and Type II error probabilities, α^* and β^* , corresponding to the 'Reject' or 'Accept' decision (see Table 11).




Figure 7: The acceptance and rejection boundaries of B_m for the 24 data points of Table 10

Table 10: The values of Bayes factor and the boundaries based on it for each data point among different cases with the Jeffrey's prior.

Test	m	X_m	$\hat{\gamma}$	$B_m^{(1)}$	$r^{(1)}$	$a^{(1)}$	$B_m^{(2)}$	$r^{(2)}$	$a^{(2)}$	$B_m^{(3)}$	$r^{(3)}$	$a^{(3)}$
1	12	1	0.0909	0.0348	1	2.2505	34.7839	1	5.2308	997.4399	1	2.3824
2	18	5	0.3846	0.8570	1	3.4458	30.4686	1	7.0875	34.5543	0.5104	1
3	24	11	0.8462	5.7079	1	2.9086	16.6892	1	5.6013	1.9239	1	1.8636
4	30	15	1.0000	6.9221	1	3.7844	13.8442	1	6.9070	1.0000	1	1.7492
5	34	15	0.7895	5.8156	1	2.8478	23.5774	1	7.7198	3.0541	1	1.6929
6	40	17	0.7391	5.0778	1	3.5652	29.6152	1	6.1286	4.8323	1	1.6267
7	46	20	0.7692	5.7730	1	2.8578	30.6617	1	7.1120	4.3113	0.6408	1
8	67	34	1.0303	10.2206	1	4.1572	18.6318	1	8.8826	0.8230	1	1.2029
9	78	39	1.0000	11.1045	1	4.3958	22.2090	1	9.0068	1.0000	0.7064	1
10	100	44	0.7857	6.1053	1	4.7006	53.0962	1	9.0504	7.6967	1	1.3656
11	115	51	0.7969	6.4501	1	3.8165	57.2681	1	9.3841	7.8787	1	1.1532
12	135	63	0.8750	10.8056	1	4.9882	49.2625	1	8.9751	3.5590	1	1.1411
13	167	88	1.1139	12.7261	1	4.3165	16.8142	1	9.4196	0.3212	1	1.1266
14	172	91	1.1235	12.3066	1	5.1324	15.8372	1	8.7899	0.2869	1	1.2698
15	190	107	1.2892	3.7840	1	4.8263	3.9445	1	10.0463	0.0424	1	1.2555
16	197	113	1.3452	2.0676	1	4.5858	2.1082	1	9.5259	0.0196	1	1.1163
17	211	124	1.4253	0.6991	1	5.1907	0.7028	1	8.5552	0.0054	1	1.1123
18	218	130	1.4773	0.3160	1	4.9304	0.3167	1	9.9074	0.0022	0.8092	1
19	222	134	1.5227	0.1538	1	5.0959	0.1539	1	10.1571	0.0010	0.8107	1
20	231	141	1.5667	0.0653	1	4.9166	0.0653	1	9.7513	0.0004	1	1.1072
21	240	148	1.6087	0.0266	1	4.7401	0.0266	1	9.3589	0.0001	0.8171	1
22	245	153	1.6630	0.0091	1	5.4724	0.0091	1	8.7620	0.0000	1	1.1040
23	247	155	1.6848	0.0058	1	5.5520	0.0058	1	8.8709	0.0000	1	1.1036
24	251	157	1.6702	0.0067	1	4.6391	0.0067	1	9.0885	0.0000	1	1.1027

Table 11: The decision and corresponding conditional α^* and β^* for each data point among different cases with the Jeffrey's prior. (Decision: 'R' indicates Reject, 'A' indicates Accept, 'ND' indicates No Decision, 'NA' indicates No Answer.)

Test	$\hat{\gamma}$	$B_m^{(1)}$	Decision	α^* (or β^*)	$B_m^{(2)}$	Decision	α^* (or β^*)	$B_m^{(3)}$	Decision	α^* (or β^*)
1	0.0909	0.0348	R	0.0336	34.7839	A	0.0286	997.4399	A	0.0010
2	0.3846	0.8570	R	0.4615	30.4686	A	0.0319	34.5543	A	0.0256
3	0.8462	5.7079	A	0.1773	16.6892	A	0.0612	1.9239	A	0.3304
4	1.0000	6.9221	A	0.1263	13.8442	A	0.0714	1.0000	ND	NA
5	0.7895	5.8156	A	0.1490	23.5774	A	0.0462	3.0541	A	0.2449
6	0.7391	5.0778	A	0.1773	29.6152	A	0.0359	4.8323	A	0.1427
7	0.7692	5.7730	A	0.1490	30.6617	A	0.0319	4.3113	A	0.1730
8	1.0303	10.2206	A	0.0937	18.6318	A	0.0530	0.8230	R	0.4515
9	1.0000	11.1045	A	0.0937	22.2090	A	0.0462	1.0000	ND	NA
10	0.7857	6.1053	A	0.1490	53.0962	A	0.0195	7.6967	A	0.0934
11	0.7969	6.4501	A	0.1490	57.2681	A	0.0179	7.8787	A	0.0934
12	0.8750	10.8056	A	0.0937	49.2625	A	0.0213	3.5590	A	0.2071
13	1.1139	12.7261	A	0.0730	16.8142	A	0.0612	0.3212	R	0.2431
14	1.1235	12.3066	A	0.0821	15.8372	A	0.0612	0.2869	R	0.2229
15	1.2892	3.7840	ND	NA	3.9445	ND	NA	0.0424	R	0.0407
16	1.3452	2.0676	ND	NA	2.1082	ND	NA	0.0196	R	0.0192
17	1.4253	0.6991	R	0.4115	0.7028	R	0.4127	0.0054	R	0.0054
18	1.4773	0.3160	R	0.2401	0.3167	R	0.2405	0.0022	R	0.0022
19	1.5227	0.1538	R	0.1333	0.1539	R	0.1334	0.0010	R	0.0010
20	1.5667	0.0653	R	0.0613	0.0653	R	0.0613	0.0004	R	0.0004
21	1.6087	0.0266	R	0.0259	0.0266	R	0.0259	0.0001	R	0.0001
22	1.6630	0.0091	R	0.0090	0.0091	R	0.0090	0.0000	R	0.0000
23	1.6848	0.0058	R	0.0058	0.0058	R	0.0058	0.0000	R	0.0000
24	1.6702	0.0067	R	0.0067	0.0067	R	0.0067	0.0000	R	0.0000